Core Viewpoint - Hengtong Optic-electric Co., Ltd. (亨通股份) reported its half-year financial results for 2025, highlighting significant institutional investment and changes in public fund holdings [1] Institutional Investment - As of August 25, 2025, six institutional investors disclosed holdings in Hengtong shares, totaling 1.168 billion shares, which represents 39.27% of the company's total equity [1] - The institutional investors include Hengtong Group Co., Ltd., Suzhou Hengtong Yongxu Venture Capital Partnership, Zhangjiagang Puxin Enterprise Management Consulting Partnership, Jinan Taixiang Investment Partnership, Hangzhou Dunxin Asset Management Co., Ltd., and Nanhua Zhongzheng Hangzhou Bay Area ETF [1] - Compared to the previous quarter, the total institutional holding percentage increased by 2.84 percentage points [1] Public Fund Holdings - During this reporting period, one new public fund was disclosed, namely Nanhua Zhongzheng Hangzhou Bay Area ETF [1] - One public fund, the Everbright Pramerica Chengxin Mixed A, was not disclosed in this period compared to the previous quarter [1]

Core Viewpoint - The company has announced significant governance changes, including the cancellation of the supervisory board and amendments to the company’s articles of association, aimed at enhancing corporate governance and operational efficiency [58][59]. Group 1: Company Overview - The company is Zhejiang Hengtong Holding Co., Ltd., with the stock code 600226 [52]. - The company’s board of directors and supervisory board ensure the accuracy and completeness of the semi-annual report [1][53]. Group 2: Financial Data - The semi-annual report for 2025 has been approved by the board and supervisory board, confirming that it reflects the company's financial status and operational results accurately [53][54]. Group 3: Important Matters - The company plans to establish a small variety amino acid production base in Hohhot, Inner Mongolia, which will add 11,880 tons/year of production capacity, including L-Tryptophan (7,380 tons/year), L-Arginine (2,100 tons/year), and L-Isoleucine (2,400 tons/year) [4]. - The board has proposed to revise the articles of association, including the removal of the vice-chairman position and the supervisory board, transferring its powers to the audit committee [58][59]. Group 4: Governance Changes - The company has proposed multiple amendments to governance documents, including the rules for shareholder meetings, board meetings, and various management systems, all of which require approval at the upcoming shareholders' meeting [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49].

Group 1 - The company has revised its articles of association, changing "shareholders' meeting" to "shareholders' assembly" and removing references to "supervisors" and "supervisory board," with adjustments made to "audit committee" [1] - The revised articles of association will require approval from the shareholders' assembly and authorization for the chairman or designated representative to handle registration with the industrial and commercial registration authority [1] - The company plans to revise several governance documents, including the "Rules of Procedure for Shareholders' Meetings" and "Rules of Procedure for Board Meetings," which will also need approval from the shareholders' assembly [1] Group 2 - The company announced its half-year operating data for 2025, which is required by the Shanghai Stock Exchange's self-regulatory guidelines [2] - The announcement includes details on production, sales, and revenue of relevant products, as well as price fluctuations of related products and raw materials [2] Group 3 - The company will hold a half-year performance briefing on September 11, 2025, to discuss its operating results and financial status with investors [4][5] - The briefing will be conducted online, allowing investors to submit questions in advance [6][8] Group 4 - The company announced the second extraordinary shareholders' meeting for 2025, scheduled for September 16, 2025, with both on-site and online voting options available [17][18] - The meeting will discuss various proposals that have already been approved by the board of directors [18][19]

证券代码：600226 证券简称：亨通股份 公告编号：2025-045 浙江亨通控股股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 16 日 13 点 00 分 召开地点：浙江省湖州市德清县玉屏路地理信息小镇 C15 幢公司会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 投票，应按照《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等 有关规定执行。 (七)涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类型 至2025 年 9 月 16 日 序号 议案名称 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东 大会召开当日的交易 ...

浙江亨通控股股份有限公司 投资者关系管理规范 第一章 总则 第一条 为规范浙江亨通控股股份有限公司（以下简称"公司"）投资者关 系管理工作，加强公司与投资者之间的有效沟通，促进公司完善治理，提高公司 质量，切实保护投资者特别是中小投资者合法权益，根据《中华人民共和国公司 法》《中华人民共和国证券法》《关于进一步加强资本市场中小投资者合法权益 保护工作的意见》《上市公司投资者关系管理工作指引》《上海证券交易所股票 上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《浙 江亨通控股股份有限公司章程》（以下简称"《公司章程》"）等有关法律法规 和规章，结合本公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 上市公司的了解和认同，以提升上市公司治理水平和企业整体价值，实现尊重投 资者、回报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的目的： （一）通过充分的信息披露加强与投资者的沟通，促进投资者对公司的了解 和认同；提升公司的诚信度，建立公司良好的资本市场形象； （二 ...

Core Viewpoint - The report evaluates the risk management and financial status of Hengtong Financial Co., Ltd., a non-bank financial institution controlled by Hengtong Group, highlighting its compliance with regulatory requirements and effective internal controls [2][15]. Group 1: Company Overview - Hengtong Financial Co., Ltd. is a non-bank financial institution approved by the State Council, with a registered capital of 1.4 billion yuan and a shareholding structure where Hengtong Group holds 52% and Jiangsu Hengtong Optic-Electric Co., Ltd. holds 48% [2][15]. - As of June 30, 2025, the total assets of the financial company amounted to 6.069 billion yuan, with total liabilities of 4.406 billion yuan and owner's equity of 1.663 billion yuan [12]. Group 2: Internal Control and Risk Management - The company has established a robust internal control system, including a clear governance structure with a board of directors, supervisory board, and various committees responsible for risk management and internal controls [3][4][6]. - As of June 30, 2025, the company has implemented 220 internal governance regulations, with 3 new regulations added, 11 revised, and 4 abolished [6][12]. Group 3: Financial Performance - For the first half of 2025, the financial company reported a total operating income of 45.0072 million yuan, with a total operating profit of 33.9862 million yuan and a net profit of 26.6420 million yuan [12][13]. Group 4: Regulatory Compliance - The financial company meets all regulatory indicators as per the "Enterprise Group Financial Company Management Measures," with no significant deficiencies identified in its risk control systems [13][15]. - The company has established an anti-money laundering framework, with no reported suspicious transactions during the evaluation period [13].

证券代码：600226 证券简称：亨通股份 公告编号：2025-041 浙江亨通控股股份有限公司 关于修订《公司章程》及制定、修订公司部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江亨通控股股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日召开了第 九届董事会第二十二次会议，审议通过了《关于修订 <公司章程> 的议案》。现将相关 情况公告如下： 一、取消监事会的情况 为进一步完善公司治理，根据《公司法》《上海证券交易所股票上市规则》等相 关法律、法规、规范性文件的规定，公司拟取消监事会，监事会的职权由董事会审计 委员会行使。《公司监事会议事规则》等监事会相关制度相应废止。 在公司股东大会审议通过取消监事会事项之前，公司第九届监事会仍将严格按照 有关法律、法规和《公司章程》的规定继续履行监督职能，维护公司和全体股东利益。 二、《公司章程》的修订情况 根据《公司法》《上海证券交易所股票上市规则》等相关法律、法规、规范性文 件要求，公司拟在董事会架构中取消副董事长设置，结合公司治理结构调整等实 ...

Core Viewpoint - Zhejiang Hengtong Holdings Co., Ltd. disclosed its 2025 semi-annual operational data related to the industry, highlighting production, sales, and revenue figures for key products, as well as price fluctuations for both products and raw materials [1]. Group 1: Production, Sales, and Revenue - The production volume of L-Tryptophan reached 1,940.40 tons, with sales of 2,007.39 tons, generating a revenue of 86.96 million yuan [1]. - The steam product had a production volume of 856,866 tons, with sales of 545,515 tons, resulting in a revenue of 113.83 million yuan [1]. Group 2: Price Fluctuations - The selling price of L-Tryptophan decreased by 28.92%, from 60,951.41 yuan/ton to 43,322.28 yuan/ton [1]. - The selling price of steam also saw a decline of 9.25%, from 229.95 yuan/ton to 208.68 yuan/ton [1]. Group 3: Raw Material Price Changes - The average procurement price of glucose in the first half of 2025 was 2,200.53 yuan/ton, down 9.61% from 2,434.61 yuan/ton in the same period of 2024, primarily due to changes in corn starch prices [1]. - The procurement price of coal decreased by 6.06%, from 732.36 yuan/ton to 687.97 yuan/ton, attributed to changes in the supply and demand dynamics of the coal market [1].

Overview - The company has announced the reversal of asset impairment provisions due to a favorable court ruling regarding a lawsuit against a partner for the return of a transaction deposit [1][2]. Group 1: Asset Impairment Provision Reversal - The company had previously recorded an impairment provision of 266.2 million yuan related to a transaction with the partner, which was not fulfilled [1]. - The Zhejiang Deqing County People's Court ruled in favor of the company in the lawsuit concerning the transaction deposit, leading to the execution phase of the case [2]. - The company has received 21.38 million yuan from the execution of the lawsuit and 0.5568 million yuan from the liquidation of a subsidiary, allowing for a total reversal of 21.94 million yuan in bad debt provisions [2]. Group 2: Financial Impact - The reversal of the bad debt provision will increase the company's total profit for the current period by 21.94 million yuan, although this figure is unaudited and subject to final annual audit results [2]. - The reversal complies with relevant accounting standards and does not harm the interests of the company or its shareholders, ensuring that normal operations remain unaffected [2].

证券代码：600226 证券简称：亨通股份 公告编号：2025-043 浙江亨通控股股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 9 月 11 日(星期四)13:00-14:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ? 投资者可于 2025 年 9 月 4 日(星期四)至 9 月 10 日(星期三)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱（600226@zjhtkg.com） 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 浙江亨通控股股份有限公司（以下简称"公司"）已于 2025 年 8 月 26 日发布 公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年 度经营成果、财务状况，公司计划于 2025 年 9 月 11 ...